View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
August 2, 2021

Misonix’s proposed merger with Bioventus faces investigation

Bioventus expects the Misonix merger to generate a pure-play regenerative medicine and orthopaedics company.

Stockholder rights law firm Bragar Eagel & Squire has launched an inquiry into Bioventus ’ proposed acquisition of therapeutic ultrasonic technology developer Misonix for a total consideration of $518m.

Free Report
img

What is driving M&A activity in the MedTech space?

The COVID-19 pandemic has left an indelible mark on the MedTech landscape. Changes in how healthcare is delivered, and new treatment modalities, are creating opportunities and challenges for both new and traditional players. As companies sought out opportunities during the pandemic-driven downturn, the number and value of mergers and acquisition deals in the MedTech space increased. Companies worked to reposition themselves in the newly aligned healthcare world, but with further economic turmoil expected: will these trends be repeated? And what tech areas should firms be looking to expand their capabilities into? GlobalData’s report, “Themes driving M&A activity in the Medical Devices Sector, Q1 2022,” draws upon GlobalData’s extensive MedTech deals databases, highlighting major trends and hot themes in M&A activity. This report will assist you in:
  • Understanding value and volume trends in M&A from Q1 2018 to Q1 2022
  • Understanding regional trends in M&A activity
  • Understanding which medical device sectors are leading M&A activity, and which are lagging
  • Understanding the leading tech trends in Q1 2022 M&A activity
  • Knowing the key deals that occurred during Q1 2022
Download the full report to understand what to expect and how to align your business for success.
by GlobalData
Enter your details here to receive your free Report.

Bragar Eagel & Squire will investigate if the officers or directors of Misonix breached their fiduciary duties or violated the federal securities laws concerning the merger.

Last month, Bioventus signed into a definitive agreement to acquire Misonix in a cash-and-stock deal.

As per the terms of the deal, approved by the boards of directors of both companies, stakeholders of Misonix will get nearly $518m from Bioventus .

Misonix stockholders can choose either 1.6839 shares of Bioventus class A common stock or $28 in cash without interest for each share of Misonix they own.

On concluding the acquisition, the merged entity will work as Bioventus and will use the international strengths of both companies as a pure-play regenerative medicine and orthopaedics company.

Furthermore, the business combination will result in a medical technology company with products and dedicated salesforces catering to a $15bn total addressable market in the hospital, ambulatory surgical centre and office care settings.

The merged company will boost Misonix ’s BoneScalpel and Nexus usage via Bioventus ’ broad spine surgical solutions footprint. It will also enhance Bioventus ’ lower extremity offerings and the commercial presence to expedite growth.

Furthermore, the business combination expands Misonix ’s global access using direct channels and infrastructure of Bioventus in the Netherlands, Canada, Germany and the UK.

Commenting on the probe into this merger, Bragar Eagel & Squire said: “Bragar Eagel & Squire is concerned that Misonix ’s board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement.

“Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for Misonix ’s stockholders.”

Subject to regulatory and other approvals and customary closing conditions, the deal is anticipated to conclude in the fourth quarter of this year.

In July last year, Bioventus invested $15m in CartiHeal, an Israel-based developer of Agili-C implant for the treatment of joint surface lesions in traumatic and osteoarthritic joints.

Related Companies

Free Report
img

What is driving M&A activity in the MedTech space?

The COVID-19 pandemic has left an indelible mark on the MedTech landscape. Changes in how healthcare is delivered, and new treatment modalities, are creating opportunities and challenges for both new and traditional players. As companies sought out opportunities during the pandemic-driven downturn, the number and value of mergers and acquisition deals in the MedTech space increased. Companies worked to reposition themselves in the newly aligned healthcare world, but with further economic turmoil expected: will these trends be repeated? And what tech areas should firms be looking to expand their capabilities into? GlobalData’s report, “Themes driving M&A activity in the Medical Devices Sector, Q1 2022,” draws upon GlobalData’s extensive MedTech deals databases, highlighting major trends and hot themes in M&A activity. This report will assist you in:
  • Understanding value and volume trends in M&A from Q1 2018 to Q1 2022
  • Understanding regional trends in M&A activity
  • Understanding which medical device sectors are leading M&A activity, and which are lagging
  • Understanding the leading tech trends in Q1 2022 M&A activity
  • Knowing the key deals that occurred during Q1 2022
Download the full report to understand what to expect and how to align your business for success.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network